India Pharma Sector - IPM Growth On An Uptrend In August Led By Select Therapies: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
India pharma market growth was 17.7% YoY in August 2021 versus 13.7 % YoY in July 2021.
Respiratory/analgesics/anti-infectives grew 38.2%/32.4%/29.2% YoY.
Respiratory sales growth increased sequentially, with 38.2% YoY growth achieved in August-21 (versus 22.8% YoY growth in July-21).
For the quarter ended August-21, YoY growth stood at 15.2% YoY.
Price growth of 5.8% YoY and new product growth of 3.5% YoY was further boosted by 5.9% YoY volume growth.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.